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Abstract
The development of metastases has been shown to be associated with the microvascular density of the primary
tumor in some clinical studies and with the extent of hypoxia in others. The aim of this study was to investigate the
validity of these apparently inconsistent observations and to reveal possible links between them. Xenografted
tumors of nine melanoma cell lines established from patients with diseases differing in aggressiveness were stud-
ied. The aggressiveness of the cell lines was assessed by measuring their lung colonization potential, invasive-
ness, angiogenic potential, and tumorigenicity. Spontaneous metastasis was assessed in untreated mice and
mice treated with neutralizing antibody against vascular endothelial growth factor A (VEGF-A) or interleukin 8
(IL-8). Microvascular density was scored in histologic preparations. Hypoxic fractions were measured by using a
radiobiologic assay and a pimonidazole-based immunohistochemical assay. The aggressiveness of the melanoma
lines reflected the aggressiveness of the donor patients’ tumors. The metastatic propensity was associated with
the microvascular density but not with the hypoxic fraction. Anti–VEGF-A and anti–IL-8 treatments resulted in de-
creased microvascular density and reduced incidence of metastases in all lines. Large hypoxic fractions were not a
secondary effect of high cellular aggressiveness, whereas the microvascular density was associated with the cel-
lular aggressiveness. The metastatic propensity was governed by the angiogenic potential of the tumor cells. The
differences in microvascular density among the lines were most likely a consequence of differences in the con-
stitutive angiogenic potential rather than differences in hypoxia-induced angiogenesis. VEGF-A and IL-8 may be
important therapeutic targets for melanoma.
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Introduction
Tumors gradually accumulate stable and unstable genomic alterations
during growth, resulting in the development of an increasing number
of aggressive phenotypic traits with time, a process termed malignant
progression [1,2]. The final stage of the malignant progression is the
development of cell variants showing invasive growth in surrounding
normal tissues and metastatic spread to distant organ sites. The de-
velopment of metastatic cell phenotypes has been suggested to be a
result of genomic instability caused by defects in regulatory genes,
including oncogenes, tumor suppressor genes, and other genes in-
volved in signal transduction, DNA replication, cell cycle regulation,
DNA repair, and apoptosis [2,3].
Side by side with the generation of aggressive cell phenotypes, tu-
mors develop an abnormal microvasculature showing loss of hierarchy,
increased intervessel distances, elevated geometric resistance, and inad-
equate blood flow. These abnormalities result in a pathophysiological
tumor microenvironment characterized by low glucose concentrations,
high lactate concentrations, acidic extracellular pH, elevated interstitial
fluid pressure, and low oxygen tensions [4,5]. Regions with hypoxic
tissue are a characteristic feature of many primary tumors [6,7].
Clinical investigations involving several histologic types of can-
cer have shown that patients with highly hypoxic primary tumors
Abbreviations: IL-8, interleukin 8; TD50, tumor dose 50 (cell number resulting in tumor
growth in 50% of the inoculation sites); VEGF-A, vascular endothelial growth factor A
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may have an increased frequency of locoregional treatment failure
after radiation therapy, elevated incidence of regional and distant
metastases, and poor disease-free and overall survival rates [7]. Multiple
mechanisms may link tumor hypoxia to metastasis [8–10]. Hypoxia
followed by reoxygenation may induce DNA double-strand breaks
leading to genomic instability and provide a physiological pressure se-
lecting for aggressive cell phenotypes [11,12]. Furthermore, tumor
hypoxia activates several transcription factors, including hypoxia-
inducible factor 1, leading to upregulated expression of a large number
of gene products known to promote invasive growth and metastatic
dissemination [13].
There is also significant evidence that cancer metastasis may be de-
termined by the angiogenic potential of the primary tumor rather than
the extent of hypoxia. Thus, clinical studies involving primary tumors
in many organs have shown associations between incidence of me-
tastases and the microvascular density in vascular hot spots in the tu-
mor periphery [14,15]. The metastatic propensity of tumors may be
influenced by the angiogenic potential of the tumor cells by several
mechanisms. High angiogenic activity in the tumor periphery may
promote invasive growth, and the microvascular networks of highly
angiogenic tumors may show high vessel density and are composed
of immature vessels that are leaky and have fragmented basement
membranes and, therefore, may facilitate tumor cell intravasation
[16]. Furthermore, elevated capacity to induce neovascularization
may increase the probability of tumor cells trapped in secondary organ
capillary beds to give rise to macroscopic tumor growth [16].
Although tumor hypoxia is partly a consequence of poor oxygen
supply owing to inadequate vascularization [4], the associations be-
tween tumor hypoxia and metastasis and the associations between
microvascular density and metastasis observed in clinical studies are
not necessarily mutually exclusive. However, the mechanisms con-
necting these two sets of observation are not understood. It has been
hypothesized that the most aggressive cell phenotypes may give rise
to tumors with particularly large fractions of hypoxic tissue as well as
particularly high microvascular density as a consequence of hypoxia-
induced angiogenesis [17]. To investigate the validity of this hypothe-
sis, we established cell lines from metastases of melanoma patients with
diseases differing significantly in aggressiveness and measured the
metastatic propensity, the fraction of hypoxic cells, and the micro-
vascular density of xenografted tumors initiated from the cell lines. Be-
cause melanoma cells show large secretion of the proangiogenic factors
vascular endothelial growth factor A (VEGF-A) and interleukin 8
(IL-8) [18,19], effects of anti–VEGF-A treatment and anti–IL-8 treat-
ment on microvascular density and metastasis were also investigated.
In this article, we show that the aggressiveness of the cell lines and the
metastatic propensity of the xenografted tumors reflected the aggres-
siveness of the donor patients’ tumors. Moreover, we present signifi-
cant evidence that the metastatic propensity of the xenografted tumors
was determined primarily by the microvascular density in the tumor
periphery rather than by the fraction of hypoxic tumor cells and that
anti–VEGF-A treatment and anti–IL-8 treatment resulted in reduced
microvascular density in the tumor periphery and decreased incidence
of metastases.
Materials and Methods
Donor Patients’ Tumors
Nine patients admitted to the Norwegian Radium Hospital for
the treatment of malignant melanoma were donors of tumor tissue
(Table 1). The patients had developed regional subcutaneous and
lymph node metastases at the time of initial diagnosis. Surgical speci-
mens were obtained from large subcutaneous lesions before initiation
of chemotherapy.
Cell Lines
Permanent cell lines, one from each of the nine patients, were es-
tablished in monolayer culture. The experimental procedure and four
of the cell lines have been described in detail previously [20]. Beyond
passage 50, the cell lines were found to be stable with respect to sev-
eral parameters, including growth rate, plating efficiency in vitro,
DNA content, radiation sensitivity in vitro, and lung colonization
potential in vivo. Large stocks of cells in passages 50 to 100 were
frozen and stored in liquid nitrogen. These stocks were verified to
be free from Mycoplasma contamination. The cells used in the pres-
ent experiments were taken from our frozen stock and were main-
tained in monolayer culture in RPMI 1640 (25 mM HEPES and
L-glutamine) supplemented with 13% bovine calf serum, 250 mg/L
penicillin, and 50 mg/L streptomycin.
Mice
Adult (8-10 weeks) female BALB/c nu/nu mice, bred and main-
tained as described elsewhere [21], were used as host animals for xe-
nografted tumors. The animal experiments were approved by the
institutional committee on research animal care and were done ac-
cording to the USPHS Policy on Humane Care and Use of Labora-
tory Animals.
Tumors
Xenografted tumors for assessment of volumetric growth rate, frac-
tion of hypoxic cells, microvascular density, and metastatic propensi-
ty were initiated by injecting aliquots of 5.0 × 104 to 2.5 × 106 cells
intradermally (ID) into the left mouse flank. Tumor volume (V ) and
tumor volume doubling time (Td) were calculated as V = π/6 × a × b
2
and Td = ln2 × t/(lnVt − lnV0), where a is the longer and b is the
shorter of two perpendicular diameters, and Vt and V0 represent the
tumor volume at time t and time zero, respectively.
Invasiveness
Cell invasiveness was determined by using 24-well Matrigel inva-
sion chambers with 8-μm pore polycarbonate membranes precoated
with a thin layer of Matrigel Basement Membrane Matrix (BD Bio-
sciences, Cowley, UK). The chambers were rehydrated in serum-free
medium as described by the manufacturer. Complete medium (750 μl)
Table 1. Clinical Characteristics of the Donor Patients.
Patient Age (Year) Sex Primary Tumor Breslow
Index (mm)
Stage Cause of Death
A-07 50 Male Upper limb 3.8 III-N3 Lung Mets
C-10 27 Female Trunk 4.5 III-N2 Liver Mets
D-12 38 Female Trunk 8.3 III-N3 Lung Mets
R-18 45 Female Neck 7.4 IV-M1a Lymph node Mets
S-20 64 Male Face 4.2 III-N3 Lymph node Mets
T-22 62 Male Neck 5.2 III-N3 Lung Mets
U-25 49 Male Trunk 5.0 III-N3 Brain Mets
V-27 35 Female Lower limb 6.5 III-N2 Lung Mets
Z-98 22 Male Trunk 4.0 IV-M1a Lung Mets
Mets indicates metastases.
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was used as chemoattractant. Suspensions of 2.5 × 104 to 7.5 × 104
cells in 500 μl of complete medium were added to the wells and incu-
bated for 24 hours at 37°C in 5% CO2 in air. Cells remaining on the
upper membrane surface were removed, whereas the cells on the lower
surface were fixed in methanol, stained with hematoxylin, and counted
by examining 10 randomly selected fields at ×40 magnification. Fur-
ther details have been reported elsewhere [22].
Lung Colonization Potential
Aliquots of 1.0 × 104 to 2.0 × 106 cells in 0.2 ml of HBSS were
inoculated into the lateral tail vein [22]. The mice were killed and
autopsied 2 to 8 weeks after the cell inoculation. The lungs were re-
moved and fixed in the Bouin solution for 24 hours, and the number
of surface colonies was determined by stereomicroscopy.
Tumorigenicity
Serial dilutions of cell suspensions were inoculated ID or intracra-
nially (IC) for tumor formation [23]. The inoculation point in the
intradermal assay lay above the subcutaneous muscle tissue in the
deeper part of the dermis. The mice were examined twice weekly
for up to 120 days after the inoculations, and an inoculation was
scored as positive if a tumor with a longest diameter of at least
8 mm was observed. The inoculation point in the intracranial assay
lay ∼2 mm anterior to the coronal and ∼2 mm lateral to the sagittal
suture lines. The mice were examined daily for up to 90 days after
the inoculations. Positive transplantation was detected by the develop-
ment of progressive neurologic signs, which were evident 1 to 2 days
before death. Moribund mice were killed, and the presence of tumor
was confirmed by autopsy and histologic examination. In both assays,
the percentage of positive inoculations was plotted versus cell number,
and the cell number resulting in 50% positive inoculations (ID TD50
or IC TD50) was determined by probability regression analysis.
Angiogenesis
Angiogenic potential was measured by using an intradermal angio-
genesis assay [20]. Aliquots of 1.0 × 106 cells in 10 μl of HBSS were
inoculated, and the recipient mice were killed 7 days later when small
tumors had developed in the inoculation sites. The tumors with sur-
rounding skin were removed, and the vessels in the dermis oriented
toward the tumors were counted by using a stereomicroscope.
Fraction of Radiobiologically Hypoxic Cells
Hypoxic fractions were determined by using the paired survival curve
method [24]. Tumors were irradiated at a dose rate of 5.1 Gy/min by
using an x-ray unit operated at 220 kV, 19 to 20 mA, and with 0.5-mm
Cu filtration. Hypoxic tumors were obtained by occluding the blood
supply with a clamp 5 minutes before irradiation. Tumor cell survival
was measured in vitro [25]. Briefly, the tumors were resected immedi-
ately after irradiation, minced in cold HBSS, and treated with an en-
zyme solution (0.2% collagenase, 0.05% Pronase, and 0.02% DNase)
at 37°C for 2 hours. Trypan blue–negative cells were plated in 25-cm2
tissue culture flasks and incubated at 37°C for 14 days for colony for-
mation. The cell-surviving fraction of an irradiated tumor was calcu-
lated from the plating efficiency of the cells of the tumor and the
mean plating efficiency of the cells of six untreated control tumors. Cell
survival curves were established for clamped and unclamped tumors,
and the fraction of radiobiologically hypoxic cells was calculated from
the vertical displacement of the curves [24].
Immunohistochemical Assessment of Tumor Hypoxia and
Microvascular Density
Pimonidazole [1-[(2-hydroxy-3-piperidinyl)-propyl]-2-nitroimidazole],
administered as described previously [24], was used as a marker of
tumor hypoxia, and CD31 was used as a marker of tumor endothe-
lial cells. Tumors were fixed in phosphate-buffered 4% paraformal-
dehyde for detection of hypoxia and in liquid nitrogen for detection
of endothelial cells. Immunohistochemistry was carried out by using
an avidin-biotin peroxidase–based staining method [17]. An anti–
pimonidazole rabbit polyclonal antibody (gift from Professor J. Raleigh,
Department of Radiation Oncology, University of North Carolina
School of Medicine, Chapel Hill, NC) or an antimouse CD31 rat
monoclonal antibody (Research Diagnostics, Flanders, NJ) was used
as primary antibody. Diaminobenzidine was used as chromogen, and
hematoxylin was used for counterstaining. Controls included omission
of the primary antibody and incubation with blocking peptide before
staining. Quantitative studies of hypoxia were based on four cross sec-
tions of each tumor. The fraction of hypoxic cells, defined as the area
fraction of the nonnecrotic tissue showing positive pimonidazole stain-
ing, was assessed by image analysis [24]. The microvascular density
was scored in the invasive front by counting the vessels located within
a 1-mm-thick band in the tumor periphery. Three cross sections were
analyzed for each tumor.Microvessels were defined and scoredmanually
as described earlier by Weidner [14].
Metastasis
Spontaneous metastasis was studied as described elsewhere [25].
Briefly, the primary tumors were resected when they had grown to a vol-
ume of ∼400 mm3. The host mice were then examined daily for clinical
signs of metastases, and when they became moribund, they were killed
and autopsied. All organs were removed and inspected for macroscopic
tumor growth by stereomicroscopy, and the body was examined for ex-
ternal and internal lymph node metastases. All metastasis-positive mice
became moribund within 3 months after the primary tumor was re-
sected. The remaining mice were autopsied 6 months after the primary
tumor resection, and they were all metastasis-negative. The presence of
metastases was confirmed by histologic examination.
Treatment with Neutralizing Antibody
The specific roles of VEGF-A and IL-8 in tumor angiogenesis and
metastasis were investigated by treating tumor-bearing mice with neu-
tralizing antibody against these angiogenic factors, using an anti–human
VEGF-A mouse monoclonal antibody (R&D Systems, Abingdon,
UK) and an anti–human IL-8 mouse monoclonal antibody (R&D
Systems). The treatments were given in daily doses of 25 μg (VEGF-A)
or 100 μg (IL-8) for predetermined time intervals. The antibody so-
lutions were diluted in PBS and administered to the mice in volumes
of 0.25 ml by intraperitoneal injection. Control mice were treated with
an irrelevant antihuman monoclonal antibody of the same isotype as
the neutralizing antibody.
Statistical Analysis
Statistical analyses were carried out by one-way analysis of variance
followed by the Student-Newman-Keuls test (comparison of tumor
groups) or by the paired Student’s t test (effect of treatment) when the
data complied with the conditions of normality and equal variance.
Under other conditions, comparisons were done by nonparametric
analysis using the Kruskal-Wallis one-way analysis of variance on ranks
or the Wilcoxon signed rank test. Probability values of P < .05 were
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considered significant. The statistical analysis was carried out by using
the SigmaStat statistical software ( Jandel Scientific, Erkrath, Germany).
Results
Clinical Aggressiveness
The donor patients showed different metastatic patterns indepen-
dent of the location and thickness of the primary tumor (Table 1).
Two of the patients (R-18 and Z-98) presented with metastases in
distant lymph nodes. The other patients developed distant metastases
subsequent to the initial diagnosis, first in lymph nodes and then
in lung, liver, and/or brain. The rate of disease progression differed
significantly among the patients. Thus, the time from the initial di-
agnosis until the patients died of distant metastases ranged from 10
to 92 weeks. Based on this time, the tumors were divided into three
groups of three tumors each: A-07, D-12, and Z-98 (high aggressive-
ness); C-10, R-18, and V-27 (medium aggressiveness); and S-20, T-22,
and U-25 (low aggressiveness). The survival time was significantly
shorter for the patients in the high aggressiveness group than for those
in the medium aggressiveness group (P < .05) and significantly shorter
for the patients in the medium aggressiveness group than for those
in the low aggressiveness group (P < .05; Figure 1).
Aggressiveness of the Melanoma Lines Reflected the
Clinical Aggressiveness
To investigate whether the cellular aggressiveness of the melanoma
lines reflected the clinical aggressiveness of the donor patients’ tumors,
the following biologic parameters were measured: lung colonization
potential, cell invasiveness, angiogenic potential, tumor growth rate,
intradermal tumorigenicity, and intracranial tumorigenicity. The lung
colonization potential, measured as the number of lung colonies per
1.0 × 105 cells, was significantly higher for the high aggressiveness
group than for the medium aggressiveness group (P < .001) and sig-
nificantly higher for the medium aggressiveness group than for the low
aggressiveness group (P < .05; Figure 2A). Cell invasiveness was mea-
sured in vitro by using Z-98 cells as a reference in all experiments. The
percentage of cells penetrating a polycarbonate membrane relative to
that of Z-98 cells was used as a parameter for cell invasiveness. This
parameter was significantly higher for the high aggressiveness group
than for the medium aggressiveness group (P < .01) and significantly
higher for the medium aggressiveness group than for the low aggres-
siveness group (P < .01; Figure 2B). The angiogenic potential was
determined by inoculating 1.0 × 106 cells ID and counting the tumor-
oriented vessels 7 days later. The number of vessels was significantly
higher for the high aggressiveness group than for the medium aggres-
siveness group (P < .05) and significantly higher for the medium
aggressiveness group than for the low aggressiveness group (P < .01;
Figure 2C). Tumor growth rate was measured as the volume doubling
time from a volume of 200 to a volume of 400 mm3. The volume
doubling time was significantly shorter for the high aggressiveness
group than for the medium aggressiveness group (P < .05) and sig-
nificantly shorter for the medium aggressiveness group than for the
low aggressiveness group (P < .01; Figure 2D). The intradermal and
intracranial tumorigenicities were measured by using the ID TD50 and
IC TD50 values as parameters. These parameters were significantly
lower for the high aggressiveness group than for the medium aggres-
siveness group (P < .05 [ID TD50], Figure 2E ; P < .01 [IC TD50],
Figure 2F ) and significantly lower for the medium aggressiveness group
than for the low aggressiveness group (P < .05 [ID TD50], Figure 2E ;
P < .01 [IC TD50], Figure 2F).
High Fraction of Radiobiologically Hypoxic Cells Was Not
Associated with High Cellular Aggressiveness
To investigate whether the extent of hypoxia in xenografted tu-
mors of the melanoma lines was associated with the cellular aggres-
siveness, the fraction of radiobiologically hypoxic cells was measured
in tumors with volumes of ∼400 mm3 by using the paired survival
curve method. The results are presented in Figure 3, which shows the
paired survival curves for the high aggressiveness melanomas (Fig-
ure 3A), the medium aggressiveness melanomas (Figure 3B), and the
low aggressiveness melanomas (Figure 3C). The cellular radiation sen-
sitivity, given by the slopes of the curves (a steep curve corresponds to a
high radiation sensitivity), and the fraction of hypoxic cells, given by
the vertical distance between the curves (a short distance corresponds
Figure 1. Donor patients’ survival time determined as the time from the initial diagnosis until the patients died of metastatic disease. On
the basis of this time, the tumors were divided into a high aggressiveness group, a medium aggressiveness group, and a low aggres-
siveness group. The stars between the groups indicate the significance level of the difference between the groups: one star indicates
P < .05.
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to a high hypoxic fraction), differed substantially among the melanoma
lines. The three melanoma groups did not differ significantly in cel-
lular radiation sensitivity (P > .05; data not shown). The fraction of
radiobiologically hypoxic cells was significantly lower for the high ag-
gressiveness group than for the medium (P < .05) and the low (P <
.05) aggressiveness groups, but it did not differ significantly between
the medium and the low aggressiveness groups (P > .05; Figure 4A).
High Fraction of Pimonidazole-Positive Hypoxic Cells Was
Not Associated with High Cellular Aggressiveness
To investigate further whether the extent of hypoxia in xenografted
tumors of the melanoma lines was associated with the cellular aggres-
siveness, the fraction of pimonidazole-positive cells was assessed in
∼400-mm3 tumors by using an immunohistochemical assay. The tu-
mors of all lines showed highly heterogeneous staining for pimonidazole.
Necrotic regions were encompassed by a rim of pimonidazole-positive
cells, two to four cell layers thick. The periphery of tumor chords also
stained positive for pimonidazole. Moreover, foci of pimonidazole-
positive cells scattered throughout the tissue were observed in tumor
regions without necrosis. The fraction of pimonidazole-positive hyp-
oxic cells was significantly lower for the high aggressiveness group than
for the medium aggressiveness group (P < .05) and was significantly
lower for the medium aggressiveness group than for the low aggressive-
ness group (P < .01; Figure 4B).
High Microvascular Density Was Associated with High
Cellular Aggressiveness
To investigate whether the microvascular density in xenografted
tumors of the melanoma lines was associated with the cellular aggres-
siveness, the microvascular density was measured in the periphery of
Figure 2. Lung colonization potential (A), relative cell invasiveness (B), angiogenic potential (C), tumor volume doubling time (D), ID TD50
(E), and IC TD50 (F) for high aggressiveness, medium aggressiveness, and low aggressiveness melanomas. Columns indicate means of
five experiments involving 10 mice each (A), six experiments (B), 20 inoculations (C), 20 tumors (D), or five to six experiments (E and F).
Bars, SEM. The stars between the groups indicate the significance level of the difference between the groups: one star indicates P <
.05; two stars, P < .01; three stars, P < .001.
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tumors with volumes of ∼400 mm3. It differed substantially among
the melanoma lines and was significantly higher for the high aggres-
siveness group than for the medium aggressiveness group (P < .01)
and significantly higher for the medium aggressiveness group than for
the low aggressiveness group (P < .01; Figure 4C ).
High Metastatic Propensity Was Associated with High
Microvascular Density and Not with High Hypoxic Fraction
To investigate whether the metastatic propensity of xenografted
tumors of the melanoma lines was associated with the microvascular
density or the extent of hypoxia, the development of spontaneous
metastases was studied. The fraction of metastasis-positive mice was
significantly higher for the high aggressiveness group than for the me-
dium aggressiveness group (P < .01; Figure 5, A and B, no treatment)
and significantly higher for the medium aggressiveness group than for
the low aggressiveness group (P < .05; Figure 5, B and C , no treat-
ment). The propensity of the xenografted tumors to form spontaneous
metastases thus reflected the clinical aggressiveness of the donor pa-
tients’ tumors (Figure 1), and it was associated with a high microvas-
cular density in the tumor periphery (Figure 4C) but not with a high
hypoxic fraction (Figure 4, A and B).
Metastatic Propensity Was Reduced by Anti–VEGF-A and
Anti–IL-8 Treatments
To investigate whether VEGF-A and/or IL-8 played a significant
role in the metastatic process, the development of spontaneous metas-
tases was studied in mice treated with neutralizing antibody against
these angiogenic factors. The antibody treatments were given in daily
fractions from the primary tumors reached a volume of 50 mm3 (high
Figure 3. Cell survival curves for xenografted tumors of high aggressiveness melanomas (A), medium aggressiveness melanomas (B),
and low aggressiveness melanomas (C) irradiated under air breathing (○) or hypoxic (•) conditions. Points indicate geometric means of
five to seven tumors. Bars, SEM. Solid curves indicate curves fitted to the data by regression analysis.
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aggressiveness group), 100 mm3 (medium aggressiveness group), or
200 mm3 (low aggressiveness group) until they reached a volume of
400 mm3 and were resected. Compared with untreated control mice,
mice given anti–VEGF-A treatment and mice given anti–IL-8 treat-
ment showed decreased incidence of metastatic disease. The decreases
were significant for the high aggressiveness group (P = .0011, VEGF-A;
P = .0013, IL-8; Figure 5A) and the medium aggressiveness group (P =
.031, VEGF-A; P = .0011, IL-8; Figure 5B) and on the borderline of
being significant for the low aggressiveness group (P = .10, VEGF-A;
P = .08, IL-8; Figure 5C).
Microvascular Density Was Reduced by Anti–VEGF-A and
Anti–IL-8 Treatments
To investigate whether the decreased metastasis after the anti–
VEGF-A and anti–IL-8 treatments was associated with decreased mi-
crovascular density, the microvascular density in the periphery of the
primary tumors was assessed. Compared with the tumors in untreated
control mice, the tumors in mice given anti–VEGF-A treatment and
the tumors in mice given anti–IL-8 treatment showed decreased mi-
crovascular density. The decreases were significant for both treatments
and all three tumor groups (P < .01; Figure 5, D-F ).
Figure 4. Fraction of radiobiologically hypoxic cells, HFRad (A), fraction of pimonidazole-positive hypoxic cells, HFPim (B), and microvas-
cular density (C) in xenografted tumors of high aggressiveness, medium aggressiveness, and low aggressiveness melanomas. The
HFRad values were calculated from the survival curves in Figure 3. The HFPim values refer to 10 tumors of each line. The microvascular
densities refer to the periphery of eight tumors of each line. Columns indicate means. Bars, SEM. The stars between the groups indicate
the significance level of the difference between the groups: no star indicates P > .05; one star, P < .05; two stars, P < .01.
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Discussion
Tumors develop aggressive cell phenotypes during growth as a conse-
quence of stable and unstable genomic alterations in regulatory genes
[1–3]. Furthermore, they develop abnormal microvascular networks
and regions with hypoxic tissue [4–7]. The present study showed that
highly aggressive cell variants may give rise to tumors with high micro-
vascular density but may not necessarily give rise to tumors with large
fractions of hypoxic cells. Consequently, high microvascular density in
tumors may reflect the presence of particularly aggressive cell pheno-
types, whereas large hypoxic fractions are not a secondary effect of high
cellular aggressiveness.
Clinically relevant preclinical studies of associations between the
metastatic propensity of primary tumors and their physiological prop-
erties require the use of multiple tumor lines because each tumor line
represents a single patient, whereas individual tumors of the same
line represent copies of the same tumor. By including many copies
of the same tumor line in preclinical studies, the uncertainty in the
measurements can be reduced significantly compared with that in
the clinic. Cell lines established from subcutaneous metastases of nine
melanoma patients were used as model systems in the present work.
On the basis of the aggressiveness of the donor patients’ diseases, the
cell lines were divided into three groups of high, medium, or low ag-
gressiveness. By measuring the lung colonization potential, invasive
potential, angiogenic potential, ID TD50, and IC TD50 of the cell
lines and the growth rate and metastatic propensity of xenografted
tumors initiated from the cell lines, it was shown that the aggres-
siveness of the melanoma lines mirrored the aggressiveness of the
donor patients’ tumors. Consequently, the melanoma lines should be
adequate models for answering the questions addressed in the work
reported here.
Figure 5.Metastatic frequency (A-C) and tumor microvascular density (D-F) in untreated mice, mice given anti–VEGF-A treatment, and mice
given anti–IL-8 treatment for high aggressiveness (A, D), medium aggressiveness (B, E), and low aggressiveness (C, F)melanomas. Columns
and points in panels A to C indicatemeans and individual values of two experiments involving 10mice each. Columns and bars in panels D to
F indicate means and SEM of 20 tumors. The stars above the treatment groups indicate the significance level of the difference between the
treatment group and the untreated control group: no star indicates P > .05; one star, P < .05; two stars, P < .01; three stars, P < .001.
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Microvascular density was scored by counting the vessels located
within a 1-mm-thick band in the periphery of the melanoma xeno-
grafts. In most clinical studies showing associations between microvas-
cular density and incidence of metastases, the microvascular density
was defined as the vessel density in vascular hot spots in the invasive
front of the primary tumor [14,15]. Thus, the parameter used to de-
scribe microvascular density in the present work deviates from that
used in the clinical studies. The clinical parameter for microvascular
density was not applicable to the melanoma xenografts because the tu-
mors of most of the nine lines did not show distinct vascular hot spots.
The melanoma xenograft studies showed that the incidence of spon-
taneous metastases was strongly associated with the angiogenic poten-
tial of the tumor cells and the microvascular density of the primary
tumor. Furthermore, treatment with neutralizing antibody against
VEGF-A or IL-8 resulted in reduced primary tumor microvascular den-
sity and decreased incidence of metastatic disease. These observations
suggest that the metastatic propensity of the melanoma xenografts was
determined primarily by the angiogenic potential of the melanoma cells
and, moreover, that melanoma cells with a high angiogenic potential
gave rise to tumors with high microvascular density. The latter state-
ment is not an obvious statement because the volumetric growth rate
of the melanoma xenografts also increased with increasing angiogenic
potential. The present study is thus consistent with the clinical studies
having shown associations between tumor microvascular density, inci-
dence of metastases, and prognosis, studies that involve several histo-
logic types of cancer [14,15] including malignant melanoma [26–28].
Tumor hypoxia was assessed by measuring the fraction of radiobio-
logically hypoxic cells using the paired survival curve method and by
measuring the fraction of pimonidazole-positive cells using an immu-
nohistochemical assay. The radiobiologic assay detects acutely as well
as chronically hypoxic cells and measures the fraction of the clonogenic
cells in tumors that are hypoxic during the radiation exposure. How-
ever, because 50% radiosensitization occurs at an oxygen tension of
∼3 mm Hg, this assay detects only the most hypoxic tumor cells
[29]. Nevertheless, the fraction of radiobiologically hypoxic cells is
considered to be of greater clinical significance than hypoxic fractions
derived from nonradiobiologic assays because only clonogenic cells are
of relevance for tumor growth, metastasis, and response to treatment
[30]. The immunohistochemical assay detects primarily chronically
hypoxic cells and does not distinguish between nonclonogenic and
clonogenic cells and may thus give an erroneous estimate of the extent
of hypoxia in tumors [30]. However, because pimonidazole staining
occurs at an oxygen tension of 7.5 to 10 mm Hg, this assay detects
a broader level of tumor hypoxia [24]. Furthermore, in many of the
clinical studies having shown associations between tumor hypoxia and
incidence of metastases or metastasis-free survival, the extent of hyp-
oxia was measured immunohistochemically by using pimonidazole as
an exogenous hypoxia marker or hypoxia-inducible factor 1 or car-
bonic anhydrase IX as endogenous hypoxia markers [31].
Our study did not provide any evidence that the metastatic propen-
sity of the melanoma xenografts increased with increasing fraction of
hypoxic cells. In fact, the fraction of radiobiologically hypoxic cells did
not differ between the medium and the low aggressiveness groups and
was significantly higher for these two groups than for the high aggres-
siveness group. Moreover, the fraction of pimonidazole-positive hyp-
oxic cells was significantly higher for the low aggressiveness group
than for the medium aggressiveness group and was significantly higher
for the medium aggressiveness group than for the high aggressiveness
group. This strong tendency toward an inverse relationship between
metastatic propensity and tumor hypoxia may be a consequence of
the elevated angiogenic potential of the melanoma lines in the high
and medium aggressiveness groups. These observations thus suggest
that the fraction of hypoxic cells was not a primary determinant of
the metastatic propensity of the melanoma xenografts.
However, this suggestion does not imply that the extent of tumor
hypoxia is an unimportant factor in the metastasis of melanoma xeno-
grafts. In previous studies of the D-12 and R-18 lines, we have shown
that tumors with large fractions of hypoxic cells have a higher meta-
static potential than tumors with low hypoxic fractions [17,32]. In
the D-12 line, this effect was primarily due to hypoxia-induced up-
regulation of IL-8 [17], whereas the hypoxia-induced metastasis in
the R-18 line was mainly a consequence of upregulated expression
of urokinase-type plasminogen activator receptor [32]. Moreover, we
have observed that normoxic A-07 tumors exposed to cyclic hypoxic
stress in vivo show enhanced angiogenesis and metastasis, primarily as
a result of hypoxia-induced up-regulation of VEGF-A [33]. These
observations suggest that tumor hypoxia may promote metastasis in
melanoma xenografts by upregulating the expression of gene products
stimulating angiogenesis. Consequently, the angiogenic activity may
be a major determinant of the metastatic propensity of melanoma
xenografts, both in normoxic and hypoxic tissue regions.
The malignant progression of melanoma is characterized by distinct
sequential steps from commonly acquired melanocytic nevus through
dysplastic nevus, radial growth phase primary melanoma, and vertical
growth phase primary melanoma to melanoma metastasis [34]. There
is substantial evidence that melanoma progression requires induction
of new blood vessels. Thus, the transition from the radial to the ver-
tical growth phase, which represents a significant worsening of the
prognosis, has been shown to be dependent on neovascularization
[35,36]. The preclinical study reported here suggests that VEGF-A
and IL-8 are important proangiogenic factors in malignant melanoma
and, consequently, VEGF-A, IL-8, and their receptors may be impor-
tant targets for the treatment of this disease.
Clinical investigations have shown that invasive growth, development
of metastatic disease, and poor disease-free and overall survival rates
are associated with extensive hypoxia in the primary tumor in several
cancer types, including cervical carcinoma, head and neck carcinoma,
and soft tissue sarcoma [37–39]. In contrast, no association was found
betweenmetastatic propensity and hypoxic fraction in the present study,
most likely because the metastatic propensity of melanoma xenografts
is determined by the tumor microvascular density, and the differences
in microvascular density among lines are governed by the constitutive
angiogenic potential of the tumor cells rather than by hypoxia-induced
angiogenesis. There are several possible explanations of this disparity.
First, the metastatic propensity of cervical carcinoma, head and neck
carcinoma, and soft tissue sarcoma may be governed by tumor proper-
ties other than the angiogenic potential and the microvascular density.
Thus, preclinical studies have suggested that tumor hypoxia also may
promote metastasis by increasing the resistance to apoptosis by upreg-
ulating Mdm2 (murine double minute 2, an inhibitor of p53 transcrip-
tional activation) [40] and by increasing cell invasiveness and motility
by upregulating lysyl oxidase [41]. Furthermore, patients with cervical
carcinoma, head and neck carcinoma, and soft tissue sarcoma are
generally treated with radiation therapy, and the poor outcome of the
patients with the most hypoxic primary tumors may be a result of
hypoxia-induced radiation resistance rather than hypoxia-induced me-
tastasis, a suggestion that is consistent with a study of advanced squa-
mous cell carcinoma of the uterine cervix in our hospital [42].
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In summary, the present preclinical study involving nine humanmel-
anoma xenograft lines showed that the metastatic propensity of the lines
was associated with the microvascular density in the tumor periphery
and not with the fraction of hypoxic tumor cells, most likely because
the differences in microvascular density among the lines were governed
by the constitutive angiogenic potential rather than by hypoxia-induced
angiogenesis. Moreover, VEGF-A and IL-8 were identified as impor-
tant angiogenic factors in malignant melanoma as the vascularization
and metastasis of the xenografts were inhibited significantly by anti–
VEGF-A and anti–IL-8 treatments.
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